CENTURY THERAPEUTICS INC (IPSC) Stock Price, Quote, News and Overview
NASDAQ:IPSC - Nasdaq - US15673T1007 - Common Stock - Currency: USD
IPSC Quote, Performance and Key Statistics
0.5017
-0.03 (-5.38%)
The current stock price of IPSC is 0.5017 USD. In the past month the price decreased by -8.52%. In the past year, price decreased by -82.58%.
IPSC Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.12 | 329.14B | ||
| AMGN | AMGEN INC | 14.17 | 150.99B | ||
| GILD | GILEAD SCIENCES INC | 13.33 | 128.61B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1702.9 | 126.96B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.2 | 65.88B | ||
| ARGX | ARGENX SE - ADR | 323.56 | 37.54B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.72B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.39B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.52B | ||
| NTRA | NATERA INC | N/A | 20.79B | ||
| BIIB | BIOGEN INC | 7.22 | 17.39B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.30B |
Related stock screener links
About IPSC
Company Profile
Century Therapeutics, Inc. engages in the development of off-the-shelf cell therapies to advance the course of cancer care. The company is headquartered in Philadelphia, Pennsylvania and currently employs 140 full-time employees. The company went IPO on 2021-06-17. The firm is focused on developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies and autoimmune diseases. The firm has created allogeneic cell therapy platform that includes induced pluripotent stem cells (iPSCs), differentiation know-how to generate immune effector cells from iPSCs, or iPSC- derived cells, clustered regularly interspaced short palindromic repeats, to incorporate multiple transgenes and remove target genes. The Company’s product candidates include CNTY-101, CNTY-308, CNTY-341, CNTY-107, and CNTY-104. Its lead product candidate CNTY-101 is a CAR-iNK cell therapy with six precision gene edits in a Phase I clinical trial for patients with B-cell mediated autoimmune diseases. CNTY-308 is a CD19-targeted, iPSC derived CAR T cell therapy. CNTY-341 is a dual-targeted CD19 and CD22 iPSC-derived CAR-T cell therapy.
Company Info
CENTURY THERAPEUTICS INC
25 N 38Th Street, 11Th Floor
PHILADELPHIA PENNSYLVANIA US
CEO: Osvaldo Flores
Employees: 159
Company Website: https://www.centurytx.com/
Investor Relations: http://investors.centurytx.com
Phone: 12159814000
CENTURY THERAPEUTICS INC / IPSC FAQ
What is the stock price of CENTURY THERAPEUTICS INC today?
The current stock price of IPSC is 0.5017 USD. The price decreased by -5.38% in the last trading session.
What is the ticker symbol for CENTURY THERAPEUTICS INC stock?
The exchange symbol of CENTURY THERAPEUTICS INC is IPSC and it is listed on the Nasdaq exchange.
On which exchange is IPSC stock listed?
IPSC stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CENTURY THERAPEUTICS INC stock?
12 analysts have analysed IPSC and the average price target is 4.9 USD. This implies a price increase of 875.88% is expected in the next year compared to the current price of 0.5017. Check the CENTURY THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CENTURY THERAPEUTICS INC worth?
CENTURY THERAPEUTICS INC (IPSC) has a market capitalization of 43.17M USD. This makes IPSC a Nano Cap stock.
How many employees does CENTURY THERAPEUTICS INC have?
CENTURY THERAPEUTICS INC (IPSC) currently has 159 employees.
What are the support and resistance levels for CENTURY THERAPEUTICS INC (IPSC) stock?
CENTURY THERAPEUTICS INC (IPSC) has a resistance level at 0.55. Check the full technical report for a detailed analysis of IPSC support and resistance levels.
Is CENTURY THERAPEUTICS INC (IPSC) expected to grow?
The Revenue of CENTURY THERAPEUTICS INC (IPSC) is expected to grow by 1700.88% in the next year. Check the estimates tab for more information on the IPSC EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy CENTURY THERAPEUTICS INC (IPSC) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of IPSC, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of IPSC, evaluating the profitability, health, valuation and growth aspects
- CENTURY THERAPEUTICS INC (IPSC) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CENTURY THERAPEUTICS INC (IPSC) Sales and EPS estimates to see what analysts future expectations are.
- CENTURY THERAPEUTICS INC (IPSC) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CENTURY THERAPEUTICS INC (IPSC) Insider and Institutional Ownership to learn about the owners and their transactions.
- CENTURY THERAPEUTICS INC (IPSC) Stock Chart to make your own analysis
- CENTURY THERAPEUTICS INC (IPSC) Latest news and press-releases to stay up to date.
Does CENTURY THERAPEUTICS INC (IPSC) stock pay dividends?
IPSC does not pay a dividend.
When does CENTURY THERAPEUTICS INC (IPSC) report earnings?
CENTURY THERAPEUTICS INC (IPSC) will report earnings on 2025-05-08, before the market open.
What is the Price/Earnings (PE) ratio of CENTURY THERAPEUTICS INC (IPSC)?
CENTURY THERAPEUTICS INC (IPSC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.63).
What is the Short Interest ratio of CENTURY THERAPEUTICS INC (IPSC) stock?
The outstanding short interest for CENTURY THERAPEUTICS INC (IPSC) is 5.17% of its float. Check the ownership tab for more information on the IPSC short interest.
IPSC Technical Analysis
IPSC Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to IPSC. IPSC scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
IPSC Financial Highlights
Over the last trailing twelve months IPSC reported a non-GAAP Earnings per Share(EPS) of -1.63. The EPS increased by 28.82% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -35.83% | ||
| ROE | -78.44% | ||
| Debt/Equity | 0 |
IPSC Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to IPSC. The Buy consensus is the average rating of analysts ratings from 12 analysts.
For the next year, analysts expect an EPS growth of 34.09% and a revenue growth 1700.88% for IPSC